Bank Julius Baer & Co. Ltd Zurich Invests $7.13 Million in BioNTech SE (NASDAQ:BNTX)

Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 56,680 shares of the company’s stock, valued at approximately $7,128,000.

Several other hedge funds also recently modified their holdings of the company. Baillie Gifford & Co. increased its holdings in shares of BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after buying an additional 31,773 shares in the last quarter. FMR LLC increased its holdings in shares of BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after purchasing an additional 5,598,190 shares in the last quarter. Flossbach Von Storch SE increased its holdings in shares of BioNTech by 1.1% in the fourth quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company’s stock valued at $502,160,000 after purchasing an additional 47,236 shares in the last quarter. Fred Alger Management LLC acquired a new stake in shares of BioNTech in the third quarter valued at approximately $59,485,000. Finally, abrdn plc increased its holdings in shares of BioNTech by 70.7% in the fourth quarter. abrdn plc now owns 385,668 shares of the company’s stock valued at $43,947,000 after purchasing an additional 159,676 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BNTX shares. JPMorgan Chase & Co. lowered their price target on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and raised their price target for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Wells Fargo & Company started coverage on shares of BioNTech in a report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price target for the company. Berenberg Bank started coverage on shares of BioNTech in a report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target for the company. Finally, Canaccord Genuity Group raised their price target on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a report on Wednesday, November 27th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $142.72.

BioNTech Trading Down 1.8 %

Shares of NASDAQ BNTX opened at $108.78 on Monday. The company’s fifty day moving average is $116.91 and its 200-day moving average is $112.93. The stock has a market cap of $26.08 billion, a price-to-earnings ratio of -51.80 and a beta of 0.30. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.